Just In
- 16 min ago Aditi Rao Hydari's Double Diamond Engagement Ring Is Unique, Celebrity Wedding Rings That Are Bookmark Worthy!
- 3 hrs ago Navratri 2024 Date In April: When Will Chaitra Navratri Festival Start? Significance Of 9 Days, Deets Inside!
- 4 hrs ago Ramadan 2024: 6 Bollywood-Inspired Outfit Ideas To Shine During The Holy Month
- 6 hrs ago Personality Traits Of April Born Babies: From Being Witty, To Charismatic And More, They Are Full Of Sheer Joy
Don't Miss
- Finance Zerodha Fund House Doubles AUM To Rs 1,000 Crore In 40 Days; Says Founder Vasant Kamath
- Travel Choosing Your Next Home: Hyderabad Or Pune?
- News BJP Slams Opposition Over Mukhtar Ansari's Death, Akhilesh Yadav Seeks SC-Monitored Probe
- Sports RCB vs KKR IPL 2024: 'Virat Kohli will be fired up just looking at Kolkata dugout,' claims former India pacer
- Education National Management College begins admissions for CA and CMA courses
- Movies Shark Tank India 3 Episode Update: THIS Brand Aims To Help IIT-JEE, NEET Students In India In Special Way
- Technology Samsung Galaxy M15 5G Launch in India Teased; Could Be Priced Under Rs 15,000
- Automobiles Ather Rizta Pre-Bookings Now Open – Ola S1 & TVS iQube Rival
Bharat Biotech Submits Clinical Trial Data Of Covaxin In Children To CDSCO
Bharat Biotech, which completed the Phase 2/3 trials of Covid-19 vaccine Covaxin for use in children under 18 years of age, has submitted the data to the Central Drugs Standard Control Organisation for its verification and subsequent approval for Emergency Use Authorisation for the jab, company sources said on Wednesday.
"Covaxin clinical trial data of 2-18 years age group has been submitted to CDSCO. This is feasible due to the safety of the manufacturing platform and empirical evidence from Phase 1,2 and 3 clinical trials in adults," sources told PTI.
Chairman and Managing Director of Bharat Biotech International Ltd, Krishna Ella, had said on September 21 that the Paediatric Covaxin completed phase 2/3 trials with about 1,000 subjects and the data analysis was going on.
As part of the Phase II/III trial, the two-dose Covaxin was administered with 28 days apart.
"We will be submitting the data (to the regulator) by next week," he had said.
He also had said that Phase 2 trials of an intranasal vaccine to prevent Covid-19 were going on and expected to be over in October.
If approved, Covaxin will be the first Covid-19 vaccine that can be administered to children in India.
- wellnessWe Are Able To Predict Pandemic Based On Changes In Virus, Other Signals: Bharat Biotech Founder
- wellnessTemporarily Slowing Down Production Of Covaxin: Bharat Biotech
- wellnessIndia's Covaxin To Be Evaluated As COVID-19 Vaccine Candidate In USA
- healthNeglected Infectious Diseases May Be Tomorrow's Pandemic: Bharat Biotech Chief Dr Krishna Ella
- healthIndia-Made Covaxin Now On UK's Approved Travel List
- healthBharat Biotech Completes Phase 2/3 Trials Of Covaxin for Children Under 18 Years
- healthCOVID-19 Vaccines and Heart Attacks: New Studies Show Different Results; What Are They?
- wellnessCorbevax Will Be Allowed As A Booster For Those Fully Vaccinated With Covishield Or Covaxin
- kidsCovid-19 Vaccines For Kids: DCGI Grants Emergency Use Nod To 3 Vaccines For Different Age Group Of Children
- wellnessBooster Dose Of COVID Vaccine Needed To Fight Against Omicron: Study
- healthCovaxin Granted Emergency Use Listing In 13 Nations As On Jan 31 According To WHO: Government
- healthEach Dose Of Covishield, Covaxin Likely To Be Capped At Rs 275 After Getting Regular Market Approval